Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiac Arrhythmia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    158 result(s) found for: Cardiac Arrhythmia. Displaying page 5 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2014-000681-22 Sponsor Protocol Number: VIS-13-08 Start Date*: 2015-02-25
    Sponsor Name:ErasmusMC
    Full Title: EFFECT OF ISO-OSMOLAR CONTRAST MEDIUM ON CORONARY OPACIFICATION AND HEART RHYTHM IN CORONARY CT ANGIOGRAPHY (ISO-COR)
    Medical condition: Patients with suspected coronary artery disease and clinically referred for coronary CTA.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001785-14 Sponsor Protocol Number: STRESS-L Start Date*: 2017-11-09
    Sponsor Name:University Hospitals Birmingham NHS Foundation Trust
    Full Title: STRESS-L: STudy into the REversal of Septic Shock with Landiolol (Beta Blockade)
    Medical condition: Tachycardia in Septic Shock
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    20.0 10007541 - Cardiac disorders 10043071 Tachycardia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-002188-13 Sponsor Protocol Number: UoL001087 Start Date*: 2015-03-03
    Sponsor Name:University of Liverpool [...]
    1. University of Liverpool
    2. Alder Hey Children's NHS Foundation Trust
    Full Title: Emergency Treatment with Levetiracetam or Phenytoin in Status Epilepticus in Children (EcLiPSE) – an open label randomised controlled trial
    Medical condition: Convulsive Status Epilepticus
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10057955 Convulsive status epilepticus LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000664-31 Sponsor Protocol Number: D169DC00001 Start Date*: 2020-08-12
    Sponsor Name:AstraZeneca AB
    Full Title: A Registry-based, Randomised, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on Cardiometabolic Outcomes in Patients without Diabetes with Ac...
    Medical condition: Acute Myocardial Infarction, Heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-005326-38 Sponsor Protocol Number: DIGIT-HF Start Date*: 2015-03-19
    Sponsor Name:Hannover Medical School
    Full Title: A multicenter, randomized, double-blind, placebo-controlled study to demonstrate that digitoxin reduces a composite of overall mortality and hospitalization for worsening heart failure in patients ...
    Medical condition: Advanced systolic chronic heart failure NYHA class III-IV and EF ≤ 40% or NYHA class II and EF ≤ 30%
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000588-26 Sponsor Protocol Number: ICCE12.001 Start Date*: 2012-10-16
    Sponsor Name:Leiden University Medical Center
    Full Title: Pharmacokinetics of Levosimendan in children with acute heart failure
    Medical condition: Acute heart failure in children
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing) FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-013112-12 Sponsor Protocol Number: REGENERATE/DCM/2.0 Start Date*: 2010-04-22
    Sponsor Name:Barts & the London NHS Trust
    Full Title: Randomised Controlled Trial To Compare The effects of G-CSF(Granocyte™) And Autologous Bone Marrow Progenitor Cells On Quality Of Life And Left Ventricular Function In Patients with Idiopathic Dila...
    Medical condition: Idiopathic Dilated Cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    10056419 Dilated Cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001382-10 Sponsor Protocol Number: CS/2015/4775 Start Date*: 2019-01-21
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: Treatment of Barth Syndrome by CARDIOlipin MANipulation (CARDIOMAN): A randomised placebo controlled pilot trial conducted by the nationally commissioned Barth Syndrome Service
    Medical condition: Barth Syndrome is a rare, life threatening, genetic disease which affects young males. It is caused by abnormal fats (lipids) in the powerhouses of cells (mitochondria) and those who suffer with it...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-005022-18 Sponsor Protocol Number: PACeS Start Date*: 2022-07-26
    Sponsor Name:Icahn School of Medicine at Mount Sinai
    Full Title: Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG
    Medical condition: New-Onset Post-Operative Atrial Fibrillation after CABG
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000187-15 Sponsor Protocol Number: MK-8616-145 Start Date*: 2017-09-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecu...
    Medical condition: Reversal of neuromuscular blockade
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10018061 General anesthesia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-000619-51 Sponsor Protocol Number: FX06AQ-II-01 Start Date*: 2006-07-10
    Sponsor Name:Fibrex Medical Research & Development GmbH
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-Controlled Study to Measure the Effect of FX06 (a fibrin derived peptide Bβ15-42) on Ischemia-Reperfusion Injury in Patients Undergoing Primary Perc...
    Medical condition: Patients with acute myocardial infarction (AMI) indicated for Percutaneous Coronary Intervention (PCI).
    Disease: Version SOC Term Classification Code Term Level
    8.0 10000891 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) DK (Completed) AT (Completed) NL (Completed) CZ (Completed) BE (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022947-39 Sponsor Protocol Number: CV203-010 Start Date*: 2011-03-18
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Randomized, Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Safety, Tolerability and Effect on Atrial Fibrillation Burden of BMS-914392 in Patients with Paroxysmal Atrial Fi...
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10003661 Atrial fibrillation paroxysmal LLT
    14.1 10007541 - Cardiac disorders 10034039 Paroxysmal atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005352-41 Sponsor Protocol Number: TACT-2C-TRIAL Start Date*: 2014-09-05
    Sponsor Name:AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI CREMONA
    Full Title: A phase II randomized, open-label study evaluating the addition of trastuzumab to (nabTM)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with HER2 pos...
    Medical condition: Metastatic Breast Cancer in HER2- positive CTC with primary HER2-negative.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-009928-37 Sponsor Protocol Number: CONKO-008 Start Date*: 2009-10-21
    Sponsor Name:Charite Universitätsmedizin Berlin
    Full Title: Phase 1/2 Studie: CONKO-008 Oxaliplatin/Folinsäure/5-Fluorouracil (24h) in Kombination mit Lapatinib in der Zweitlinientherapie des Pankreaskarzinoms nach Progress unter Gemcitabin-Monotherapie
    Medical condition: Pancreatic cancer patients who failed first line therapy with gemcitabine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004822-85 Sponsor Protocol Number: ABCSG-34 Start Date*: 2012-01-05
    Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group)
    Full Title: A prospective, open, randomized, phase-II study of a therapeutic cancer vaccine (L-BLP25, Stimuvax®) in the pre-operative treatment of women with primary breast cancer
    Medical condition: primary breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001614-38 Sponsor Protocol Number: S63935 Start Date*: 2020-04-22
    Sponsor Name:UZLeuven
    Full Title: Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10038700 Respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002824-17 Sponsor Protocol Number: ACCOST-HH Start Date*: 2019-02-28
    Sponsor Name:University Medical Centre Hamburg-Eppendorf
    Full Title: Placebo-controlled, double-blind, randomized trial to assess the efficacy and safety of Adrecizumab in subjects with cardiogenic shock
    Medical condition: Cardiogenic shock
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007625 Cardiogenic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006637-19 Sponsor Protocol Number: CARDIOL100-002 Start Date*: 2022-12-01
    Sponsor Name:Cardiol Therapeutics Inc.
    Full Title: Impact of CardiolRxTM on Myocardial Recovery in Patients with Acute Myocarditis A double-blind, placebo-controlled trial (ARCHER)
    Medical condition: Acute Myocarditis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10000932 Acute myocarditis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004462-18 Sponsor Protocol Number: ARDS-MSC-205 Start Date*: 2020-06-02
    Sponsor Name:Uppsala University Hospital
    Full Title: MESENCHYMAL STROMAL CELL THERAPY FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME Validation of Mechanistic Pathways and Clinical Efficacy
    Medical condition: Acute respiratory distress syndrome (ARDS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002560-28 Sponsor Protocol Number: N19PEM Start Date*: 2020-11-13
    Sponsor Name:NKI-AVL
    Full Title: PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients.
    Medical condition: unresectable malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 19:40:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA